Items Tagged ‘immunotherapy’

June 22, 2018

Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer

By

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda (pembrolizumab) plus traditional chemotherapy compared with those who received placebo plus chemotherapy. About Lung Cancer Lung cancer remains the leading cause […]

View full entry

Tags: immunotherapy, keytruda, Lung Cancer, News, nsclc, pembrolizumab, Precision Cancer Medicine, squamous non–small-cell lung cancer


May 30, 2018

Interim Survival Data from Phase 3 Trial of DCVax®-L for Glioblastoma Reported

By

Northwest Biotherapeutics, developer of DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.  The data were collected by the independent contract research organization managing the trial, tabulated by an independent statistical firm and published with […]

View full entry

Tags: Brain Cancer, DCVax, Glioblastoma treatment, immunotherapy, News


May 29, 2018

Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit

By

The research team behind an emerging immunotherapy for cancer will present interim findings from an ongoing clinical study in patients with brain cancer at a major research meeting next month. Collaborators from organizations including Roswell Park Comprehensive Cancer Center, the Cleveland Clinic and MimiVax LLC will share data from their phase II study of SurVaxM […]

View full entry

Tags: Brain Cancer, gliblastoma, immunotherapy, News, rosell park


April 18, 2018

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

By

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people […]

View full entry

Tags: AM0010, clinical trials, immunotherapy, Interleukin-10, News, Pancreatic Cancer, pegilodecakin, Precision Cancer Medicine, treatment


March 14, 2018

CRISPR Enhances Cancer Immunotherapy

By

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells — called T cells — and supercharging them to home in on and attack specific blood cancers, such as […]

View full entry

Tags: CAR T Cells, CRSIPR, immunotherapy, Leukemia, Multiple Myeloma, News


February 26, 2018

Keytruda Improves Survival of Advanced Bladder Cancer

By

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of a clinical trial presented at the Genitourinary Cancer Symposium.1 About Bladder Cancer Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. The average […]

View full entry

Tags: Bladder Cancer, checkpoint inhibitors, immunotherapy, keytruda, News, PD-1, pembrolizumab, Precision Cancer Medicine, treatment


February 15, 2018

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer

By

CancerConnect News:  According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About Liver Cancer Liver cancer, or hepatocellular carcinoma (HCC), is the second most common cause of cancer-related deaths worldwide.2,3 […]

View full entry

Tags: checkpoint inhibitor, hepatocellular cancer, immunotherapy, keytruda, Liver Cancer, News, pembrolizumab, Precision Cancer Medicine


February 13, 2018

Keytruda Promising in PD-L1 Esophageal Cancer

By

CancerConnect News: The checkpoint inhibitor Keytruda (pembrolizumab) has been reported to produce an overall response rate of 30% in patients with PD-L1–positive, advanced esophageal cancer.1 About Keytruda Keytruda is a monoclonal antibody that helps to restore the body’s immune system in fighting cancer. It creates its anti-cancer effects by blocking a specific protein used by cancer […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, gastroesophageal junction cancer, immunotherapy, keytruda, News, pembrolizumab, Precision Cancer Medicine


February 2, 2018

PD-1 Antibody Cemiplimab Appears Promising for Treatment of Squamous Cell Carcinoma of the Skin

By

Cemiplimab an investigational human antibody targeting PD-1 (programmed cell death protein 1), is yet another “checkpoint inhibitor” that was evaluated in 82 patients with advanced cutaneous squamous cell carcinoma (CSCC).  Early trial results suggest that cemiplimab may represent a viable treatment option for individuals diagnosed with CSCC. About Cutaneous Squamous Cell Carcinoma (CSCC) CSCC is […]

View full entry

Tags: cemiplimab, immunotherapy, News, PD-1, Skin Cancer


January 30, 2018

Uterine Cancer: The Next Immunotherapy Frontier?

By

CancerConnect News: All gynecologic cancers are challenging to treat. They can be hard to find and are usually diagnosed when they are advanced. Although these cancers can be held at bay with surgery or chemotherapy, they often return and become difficult to control. Researchers at Memorial Sloan Kettering are exploring whether harnessing the power of […]

View full entry

Tags: immunotherapy, Keyruda, News, Uterine Cancer


January 25, 2018

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential treatment of patients with advanced renal cell carcinoma (RCC). About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are […]

View full entry

Tags: immunotherapy, keytruda, lenvatinib, Lenvima, News, pembrolizumab, Precision Cancer Medicine, Renal Cancer, renal cell cancer


January 17, 2018

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer

By

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical trial evaluated Keytruda in combination with Alimta (pemetrexed) and cisplatin or carboplatin chemotherapy for the first-line treatment of patients with NSCLC. Interim results […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, non-squamous, nsclc, PD1 Inhibitor, pembrolizumab, Precision Cancer Medicine


January 12, 2018

Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma

By

CancerConnect News: UCLA scientists have developed a potential new treatment for melanoma that has shown promising early clinical results.  In a two-year UCLA-led study, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug keytruda (pembrolizumab) with a herpes virus called T-VEC (talimogene laherpareovec). Researchers found that the […]

View full entry

Tags: immunotherapy, keytruda, Melanoma, News, Precision Cancer Medicine, T-VEC, targeted therapy


January 8, 2018

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer

By

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial.1 About Lung Cancer Lung cancer remains the leading cause of cancer-related deaths worldwide. In the […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, opdivo, pembrolizumab, Precision Cancer Medicine, Tecentriq


December 12, 2017

Keytruda Immunotherapy Shows Promise for Patients With Herceptin-resistant Breast Cancer

By

A combination of Keytruda (pembrolizumab) and Herceptin (trastuzumab), tested in patients with Herceptin-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for Keytruda, according to data presented at the 2017 San Antonio Breast Cancer Symposium. About HER2-Positive Breast Cancer About one in five […]

View full entry

Tags: Breast Cancer, Herceptin-resistant, immunotherapy, keytruda, News, pembrolizumab, Precision Cancer Medicine, SABCS, trastuzumab